Business
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
-- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 -- -- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses
About this update from Twist Bioscience Corporation
[{"type":"text","content":"\n-- Record Revenues in Fiscal 2021 of $132.3M; Increase of 47% over $90.1M in Fiscal 2020 --\n\n-- Growth Driven by Strength in SynBio, NGS, Biopharma Businesses --\n\n-- Expect Revenue of $183M to $193M for Fiscal 2022 --\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTwist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the fourth quarter and full year fiscal 2021 ended September 30, 2021.\n\n“Fiscal 2021 was a transformational year for Twist, as we delivered significant revenue growth by diversifying and expanding our customer base in synbio and NGS, as well as introduced new and innovative products,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “In biopharma, as of the end of September 2021, we had 34 partners, 41 active and 32 completed programs, with 35 of those programs having milestone payments and/or royalties associated with them. In addition, subject to regulatory approval, we expect to have the first Twist-discovered antibody in the clinic in 2022 and we also signed an agreement to acquire Abveris, which will augment our capabilities by adding animal-based discovery. In data storage, we achieved several technical milestones and are now preparing for early access launch with our 1-micron proof-of-concept chip.”\n\nFISCAL 2021 FINANCIAL RESULTS\n\n\nOrders: Total orders received for fiscal 2021 were $159.5 million compared to $116.7 million for fiscal 2020.\n\n\nRevenue: Total revenues for fiscal 2021 were $132.3 million compared to $90.1 million for fiscal 2020.\n\n\nCost of Revenues: Cost of revenues for fiscal 2021 was $80.6 million compared to $61.4 million for fiscal 2020.\n\n\nResearch and Development Expenses: Research and development expenses for fiscal 2021 were $69.1 million compared to $43.0 million for fiscal 2020.\n\n\nSelling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2021 were $135.9 million compared to $103.3 million for fiscal 2020.\n\n\nNet Loss: Net loss for fiscal 2021 was $152.1 million, or $3.15 per share, compared to $139.9 million, or $3.57 per share, for fiscal 2020.\n\n\nCash Position: As of September 30, 2021, the company had $477.9 million in...